Loading company…
VESSL Therapeutics develops cell and gene-based regenerative therapies for peripheral artery disease and dialysis access.
Founded in 2000 and based in Yokneam Illit, Israel, VESSL Therapeutics develops MultiGeneAngio and MultiGeneGraft for patients with advanced peripheral arterial disease and end-stage renal disease. The company raised USD 16.00 mn in Series A funding led by RunYoung Capital in April 2021. Its products are in various stages of clinical trials, and it targets North America and Europe.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in